NCT07652242
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
Recruiting
PHASE1Ages 18+InterventionalTreatmentImmunomic Therapeutics, Inc.
~60 participants
Updated 2026-08-03 on ClinicalTrials.gov
What's tested:ITI-5000 mRNA VaccinePembrolizumabOlaparibCapecitabineITI-5000 MTD (Maximum Tolerated Dose)
At a glance
Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Dose-Limiting Toxicities as Assessed by CTCAE v5.0
Measured over 21-28 days after the first vaccination
Conditions
Where it's being run
2 sites across 2 statesMichigan1
Tennessee1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of Dose-Limiting Toxicities as Assessed by CTCAE v5.021-28 days after the first vaccination